Skip to content

Clinical outcome and Quality of Life of multimodal treatment of venous malformations of the body

Clinical outcome and Quality of Life of multimodal treatment of venous malformations of the body - ARTEMIS

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
DRKS
Registry ID
DRKS00024906
Enrollment
300
Registered
2021-07-27
Start date
2021-10-13
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Q27.8 Q74.8 Q87

Interventions

Group 1: Peripheral (i.e. not in the region of the head but on the limbs or trunk) venous malformation has been diagnosed (abbreviated VM). This vascular malformation is a rare clinical picture with v

Sponsors

Klinikum der Universität München, Campus Großhadern
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age: > 4 years, < 70 years - Patients with simple peripheral (=extracranial) venous malformations according to the ISSVA (International Society for the Study of Vascular Anomalies) classification. Each patient and the corresponding diagnosis, is discussed in an interdisciplinary board for vascular anomalies before initiation of treatment. Patients with combined vascular malformations and venous malformations associated with other anomalies according to the ISSVA (International Society for the Study of Vascular Anomalies) classification - Patients with first line therapy or patients with previous alternative therapies in whom the previous treatments did not lead to durable symptom improvement - Previous surgery or sclerotherapy are not an exclusion criterion, but these patients will only be included in case of a therapy-free interval of 12 months - Adults and children will be similarly included

Exclusion criteria

Exclusion criteria: Patients with VM located in the central nervous system - Patients with VM located in abdominal parenchymal organs and the gastrointestinal tract - Patients with other high-flow vascular anomalies (e. g. vascular tumors) - Patients who have been previously treated by surgery or sclerotherapy within the last 12 months - Patients with concomitant life-limiting diseases (such as cancer) - Patients with acute inflammatory diseases - Patients with contraindications for invasive treatments o Patients with contrast agent intolerance or renal insufficiency (GFR>30ml/min) o Patients with impaired coagulation status:- Platelet count 50s - INR > 1,5 o Poor general condition with ECOC performance > 1 - Pregnant or breast-feeding women - Inability to access the VM lesion due to anatomical or pathoanatomical reason - Inability of the patient/parents to understand or follow the study protocol e.g. due to impaired mental health status - Patients/parents who refuse to give informed consent

Design outcomes

Secondary

MeasureTime frame
Therapeutic efficiency and clinical outcome of the selected therapeutic concept for venous malformation treatment at 12, 24, 36 months after completion of invasive treatment: - Physician-reported signs: general appearance (for example swelling, pulsation, pain, thrombosis, coagulopathy, cardiovascular health issues, bleeding) and location-specific signs (for example extremity length discrepancy, physical impairment) - Radiological assessment

Primary

MeasureTime frame
Patient-reported health-related Quality of Life in a multimodal therapy concept for venous malformation treatment at 6 months after completion of invasive treatment. In order to investigate the QoL in a standardized way, established questionnaires (SF-36v2, SF-10) will be used.

Countries

Austria, Germany, Switzerland

Contacts

Public ContactVanessa F. Schmidt

Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern

vanessa.schmidt@med.uni-muenchen.de+49-89-440044462

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026